| Item Type | Name |
|
Concept
|
Double-Blind Method
|
|
Academic Article
|
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
|
|
Academic Article
|
Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial.
|
|
Academic Article
|
Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group.
|
|
Academic Article
|
Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591.
|
|
Academic Article
|
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
|
|
Academic Article
|
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.
|
|
Academic Article
|
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
|
|
Academic Article
|
Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group.
|
|
Academic Article
|
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
|
|
Academic Article
|
Sulfasalazine vs. steroids in Crohn's disease: David vs. Goliath?
|
|
Academic Article
|
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
|
|
Academic Article
|
Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
|
|
Academic Article
|
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.
|
|
Academic Article
|
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.
|
|
Academic Article
|
Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis.
|
|
Academic Article
|
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
|
|
Academic Article
|
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
|
|
Academic Article
|
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial.
|
|
Academic Article
|
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
|
|
Academic Article
|
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
|
|
Academic Article
|
Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.
|
|
Academic Article
|
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
|
|
Academic Article
|
Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials.
|
|
Academic Article
|
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.
|
|
Academic Article
|
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
|
|
Academic Article
|
Unemployment and disability in patients with moderately to severely active Crohn's disease.
|
|
Academic Article
|
Natalizumab induction and maintenance therapy for Crohn's disease.
|
|
Academic Article
|
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
|
|
Academic Article
|
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
|
|
Academic Article
|
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
|
|
Academic Article
|
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.
|
|
Academic Article
|
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
|
|
Academic Article
|
Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort.
|
|
Academic Article
|
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis.
|
|
Academic Article
|
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
|
|
Academic Article
|
Testing nicotine gum for ulcerative colitis patients. Experience with single-patient trials.
|
|
Academic Article
|
Maintenance therapy with certolizumab pegol for Crohn's disease.
|
|
Academic Article
|
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.
|
|
Academic Article
|
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.
|
|
Academic Article
|
Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
|
|
Academic Article
|
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
|
|
Academic Article
|
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
|
|
Academic Article
|
Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.
|
|
Academic Article
|
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
|
|
Academic Article
|
Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study.
|
|
Academic Article
|
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
|
|
Academic Article
|
Infliximab for induction and maintenance therapy for ulcerative colitis.
|
|
Academic Article
|
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
|
|
Academic Article
|
Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease.
|
|
Academic Article
|
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
|
|
Academic Article
|
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
|
|
Academic Article
|
Cyclosporine in severe ulcerative colitis refractory to steroid therapy.
|
|
Academic Article
|
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
|
|
Academic Article
|
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
|
|
Academic Article
|
Mesalamine capsules enhance the quality of life for patients with ulcerative colitis.
|
|
Academic Article
|
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
|
|
Academic Article
|
Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
|
|
Academic Article
|
Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
|
|
Academic Article
|
Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study.
|
|
Academic Article
|
Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease.
|
|
Academic Article
|
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
|
|
Academic Article
|
Vedolizumab as induction and maintenance therapy for Crohn's disease.
|
|
Academic Article
|
Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.
|
|
Academic Article
|
A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease.
|
|
Academic Article
|
AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study.
|
|
Academic Article
|
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
|
|
Academic Article
|
Briakinumab for treatment of Crohn's disease: results of a randomized trial.
|
|
Academic Article
|
Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study.
|
|
Academic Article
|
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
|
|
Academic Article
|
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
|
|
Academic Article
|
Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).
|
|
Academic Article
|
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
|
|
Academic Article
|
Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
|
|
Academic Article
|
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.
|
|
Academic Article
|
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
|
|
Academic Article
|
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
|
|
Academic Article
|
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
|
|
Academic Article
|
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
|
|
Academic Article
|
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
|
|
Academic Article
|
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
|
|
Academic Article
|
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
|